Urinary Sodium/Potassium Ratio Screens for Hyperaldosteronism in Hypertensive Men
By LabMedica International staff writers Posted on 08 Jun 2021 |
Image: Blood test for plasma aldosterone concentration was used to screen For hyperaldosteronism in hypertensive men (Photo courtesy of VisitHealth Ltd)
Among individuals with hypertension, the prevalence of secondary hypertension has been reported to be around 10%. More than half of individuals with secondary hypertension have associated hyperaldosteronism.
Hyperaldosteronism is a medical condition wherein too much aldosterone is produced by the adrenal glands, which can lead to lowered levels of potassium in the blood (hypokalemia) and increased hydrogen ion excretion (alkalosis).
A team of medical scientists led by those at Kyoto Prefectural University (Kyoto, Japan) hypothesized that the urinary sodium/potassium ratio (Na/K) could be used as a simple, low-cost method of screening for hyperaldosteronism among individuals with hypertension in primary care and health examination settings. They recruited hypertensive individuals aged 30-69 years old who were not taking any antihypertensive medications from among participants in health examinations. Overall, 160 participants (108 men and 52 women) with a mean age of 54.3 years were eligible for this study.
Urinary Sodium (Na) and potassium (K) were measured using second morning urine samples, and the plasma aldosterone concentration (PAC) was also measured. The assay kit used for the measurement of the PAC was the SPAC-S Aldosterone Kit (TFB, Inc. Tokyo, Japan). The team evaluated the association of the second morning urine Na/K ratio (SMU Na/K) with a high PAC, defined as ≥90th percentile (24.3 ng/dL), using receiver operating characteristic (ROC) curves.
The investigators reported that the area under the ROC curve for the relationship between SMU Na/K and high PAC was 0.77 (95% confidence interval [CI]: 0.59-0.95) in men and 0.64 (95% CI: 0.36-0.93) in women. In men, SMU Na/K values of less than 1.0 could detect hyperaldosteronism with a sensitivity of 45.5%, a specificity of 97.9%, a positive predictive value of 71.4%, and a negative predictive value of 94.1%.
The authors concluded that the use of the urinary Na/K ratio may be appropriate as a method of screening for hyperaldosteronism in hypertensive men. The urinary Na/K ratio in second morning urine was inversely associated with the PAC in hypertensive men but not in women. A low urinary Na/K ratio could be a surrogate marker for the detection of a high PAC in hypertensive men. The study was published on May 17, 2021 in the journal Hypertension Research.
Related Links:
Kyoto Prefectural University
TFB Inc
Hyperaldosteronism is a medical condition wherein too much aldosterone is produced by the adrenal glands, which can lead to lowered levels of potassium in the blood (hypokalemia) and increased hydrogen ion excretion (alkalosis).
A team of medical scientists led by those at Kyoto Prefectural University (Kyoto, Japan) hypothesized that the urinary sodium/potassium ratio (Na/K) could be used as a simple, low-cost method of screening for hyperaldosteronism among individuals with hypertension in primary care and health examination settings. They recruited hypertensive individuals aged 30-69 years old who were not taking any antihypertensive medications from among participants in health examinations. Overall, 160 participants (108 men and 52 women) with a mean age of 54.3 years were eligible for this study.
Urinary Sodium (Na) and potassium (K) were measured using second morning urine samples, and the plasma aldosterone concentration (PAC) was also measured. The assay kit used for the measurement of the PAC was the SPAC-S Aldosterone Kit (TFB, Inc. Tokyo, Japan). The team evaluated the association of the second morning urine Na/K ratio (SMU Na/K) with a high PAC, defined as ≥90th percentile (24.3 ng/dL), using receiver operating characteristic (ROC) curves.
The investigators reported that the area under the ROC curve for the relationship between SMU Na/K and high PAC was 0.77 (95% confidence interval [CI]: 0.59-0.95) in men and 0.64 (95% CI: 0.36-0.93) in women. In men, SMU Na/K values of less than 1.0 could detect hyperaldosteronism with a sensitivity of 45.5%, a specificity of 97.9%, a positive predictive value of 71.4%, and a negative predictive value of 94.1%.
The authors concluded that the use of the urinary Na/K ratio may be appropriate as a method of screening for hyperaldosteronism in hypertensive men. The urinary Na/K ratio in second morning urine was inversely associated with the PAC in hypertensive men but not in women. A low urinary Na/K ratio could be a surrogate marker for the detection of a high PAC in hypertensive men. The study was published on May 17, 2021 in the journal Hypertension Research.
Related Links:
Kyoto Prefectural University
TFB Inc
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines